A week ago, Andrew Bridgen, Member of Parliament for North West Leicestershire, sent a letter to Attorney General for England and Wales, Victoria Prentis, about the emergency use authorisation for the Pfizer-BioNTech covid injection. “Please find enclosed details of an allegation of criminal conduct, by the Medicines and Healthcare products Regulatory Agency (MHRA),” he wrote. “It is clearly in the public interest – not only in the UK, but also across the world.”
In October 2022, Prentis, Member of Parliament (“MP”) for Banbury, was appointed by Installed Prime Minister Rishi Sunak as the Attorney General for England and Wales and Advocate General for Northern Ireland.
Before Prentis became an MP, she was a civil servant. It was during this time that property belonging to the Carroll Group, it is claimed, was stolen in what has been described as Britain’s longest-running, largest criminal conspiracy and corruption scandal in modern economic history. Prentis has been implicated as being an accomplice in the theft of some of this property.
Mr. Bridgen’s letter to Prentis is brief so we have republished the entire text below, followed by an image of it. It is, however, worth noting the final paragraph of his letter to understand the comment he made when he published it.
Mr. Bridgen concluded his letter: “I would be grateful for your advice as to how this matter can be progressed, as it is clearly in the public interest – not only in the UK, but also across the world. Could you please confirm safe receipt of all these documents.”
When Mr. Bridgen tweeted an image of the letter on Friday, five days after it had been sent, he accompanied it with the comment:
“To Victoria Prentis awaiting a reply … Please read.”
24 July 2023
Please find enclosed details of an allegation of criminal conduct, by the Medicines and Healthcare products Regulatory Agency (MHRA), with regard to the emergency use, authorisation and approval of the Pfizer BioNTech Covid-19 vaccines and boosters. Please note that the difference between appendix 4 and appendix 5, is that appendix 5 contains additional data regarding lymphadenopathy.
The MHRA is an Executive Agency of the Department of Health and Social Care (DHSC) and operates under the terms of a framework agreement with the Department. One of the Agency’s main statutory functions is to regulate medicines to ensure medicines for human use supplied in the UK are of an acceptable standard so that public health is thereby safeguarded, and that innovation in medicines is brought to patients safely.
The MHRA performs the functions of the Secretary of State under UK legislation relating to medicines, which includes ensuring consumer safety in relation to licensing of medicines for use in the UK. As such it is important for public confidence in medicines that the MHRA is seen as an effective safeguard of public safety. If public confidence in the safety and regulation of medicines in the UK is undermined the consequences would include serious adverse effects on patients generally and increased pressure on the NHS.
In performing its function, it is vital that the MHRA fully complies with all relevant legislation and regulations as well as the Civil Service Code in upholding core values of integrity honesty, objectivity, and impartiality. The Code requires the MHRA to set out the facts and relevant issues truthfully and to correct any errors as soon as possible. The MHRA should not deceive or knowingly mislead Ministers, Parliament or others, and legislation makes it an offence to mislead the Minister over pharmacovigilance responsibilities under Regulation 208 Human Medicines Regulation 2012 as amended.
I would be grateful for your advice as to how this matter can be progressed, as it is clearly in the public interest – not only in the UK, but also across the world. Could you please confirm safe receipt of all these documents.
[Signed] Andrew Bridgen MP